Meeting Minutes

Institution:	Retina Center of Texas - Southlake
Meeting Date:	May 05, 2026
Meeting Time	9:00 AM Central Time
Meeting Type:	Virtual Platform Teleconference (Remote) Open to the Public

Members in Attendance:

Member	Voting	Member Type
Bavaret, Tammy	Yes	Chair: Biosafety Expert/HGT Expert
Helm, Allen	Yes	Core Member: Biosafety Expert/HGT Expert
Rastein, Daniel	Yes	Core Member: Biosafety Expert/HGT Expert
Scott, Frederick	Yes	Local Unaffiliated Member
Bowers, Shawnna	No	Site Contact

Invited Members Not in Attendance:

Member	Voting	Member Type
Naik, Veena	Yes	Local Unaffiliated Member

Guests:	None
Staff:	McFarland, Christine

Call to Order: The IBC Chair called the meeting to order at 9:03 AM. A quorum was present as defined in the Sabai IBC Charter.

Conflicts of Interest: The IBC Chair reminded all members present to identify any conflicts of interest (COI). No COI was declared by any voting member of the IBC for any of the items on the agenda.

Public Comments: No public comments were made prior to or at the meeting.

Review of Prior Business: None

Previous Meeting Minutes: Minutes from 5-20-25 were reviewed and approved with no changes requested.

New Business:

PI:	Runner, Margaret MD
Sponsor:	Perceive Biotherapeutics, Inc.
Protocol:	PBI-AMD-002: A Phase 1/2a Study of VOY-101 in Subjects with Advanced Non-Neovascular Age-Related Macular Degeneration (JOURNEY)
Review Type:	Annual Review
NIH Guidelines Section:	III-C-1

Trial Summary: PBI-AMD-002 is an open-label, multi-center, two-part Phase I/IIa clinical trial sponsored by Perceive Biotherapeutics, Inc. and designed to assess the safety, tolerability, and efficacy of a single, unilateral intravitreal (IVT) injection of VOY-101 in subjects with geographic atrophy (GA) secondary to advanced non-neovascular age-related macular degeneration (AMD). VOY-101 is a recombinant adeno-associated viral vector, AAV serotype 2, containing a transgene that encodes the truncated isoform of human Complement Factor H (hCFHT). The investigational product (IP) is administered by a single intravitreal injection.

Biosafety Containment Level (BSL): The study agent VOY-101 is based on a replication-defective, recombinant Risk Group 1 AAV with no known oncogene or toxin and is manufactured in the absence of helper virus. Therefore, Biosafety Level 1 containment is the recommended containment level under the NIH Guidelines II-A-3. The administration of this agent in a clinical setting further requires compliance with the OSHA Bloodborne Pathogen Standard (29 CFR 1910.1030).

Risk Assessment and Discussion:

- The Committee reviewed the clinical trial Sponsor's study documents and the Sabai-generated comprehensive study-specific Risk Assessment which collectively provided a thorough description of the recombinant or synthetic nucleic acid molecules (investigational product/s) and the proposed clinical research activities involving the IP.
    - In summary, the primary risks in this clinical trial include potential occupational exposure from accidental spills or splashes of the IP during preparation and/or administration procedures and needlesticks due to the use of needles during preparation and/or administration. These potential risks are mitigated through a combination of relevant staff training, safe clinical practices (including Standard Precautions and sharps safety) and use of appropriate PPE (as prescribed in the Risk Assessment and documented in the IBC submission package).
    - The Site confirmed that only study personnel who have been educated on the potential biohazards and the precautions to be taken when working with the IP will handle the IP or any materials contaminated by the IP.

- The Site confirmed that study personnel are sufficiently trained in the practices and techniques required to safely work with the IP.
- The Site confirmed that staff members receive Bloodborne Pathogens training.
- Occupational Health Recommendations: None
- The Committee had no additional significant comments or recommendations regarding the description of the potential risks and occupational exposure hazards associated with handling the IP in this clinical trial, or the proposed mitigation strategies, as detailed in the Risk Assessment.

- The Committee reviewed the Site's facility details, relevant study-specific procedures and practices, the Annual Review Report, and other applicable information provided by the Site for the purposes of the IBC review.
  - The Site confirmed that the information provided in the Annual Review Report form remains accurate.
  - The Site verified that the summary of the Site's arrangements and activities with the study agent provided by the Chair was accurate.
  - In response to a question from the Committee, the Site confirmed that the vendor collects the entire biowaste container shown and replaces it with a new, empty container. The Committee asked that the slide be administratively annotated to reflect this practice.

Motion: A motion of Full Approval for the study at BSL-1 plus Standard Precautions was passed by unanimous vote. There were 0 votes against and 0 abstentions.

- Contingencies stated by the Committee: None
- Stipulations stated by the Committee: None

Review of Incidents: Nothing to report.

IBC Training: Nothing to report.

Reminder of IBC Approval Requirements.

Adjournment: The IBC Chair adjourned the meeting at 9:27 AM Central Time.

Post-Meeting Pre-Approval Note: None